Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1)

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 9065-9077

  Bonifazi, Alessandro ^a   Yano, Hideaki ^b   Del Bello, Fabio ^a   Farande, Aniket ^a   Quaglia, Wilma ^a   Petrelli, Riccardo ^a   Matucci, Rosanna ^c   Nesi, Marta ^c   Vistoli, Giulio ^d   Ferré, Sergi ^b   Piergentili, Alessandro ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BUTYLPIPERIDIN 1 YL)PROPYL] 1,2,3,4 TETRAHYDROQUINOLIN 2 ONE; 1 [3 [4 [9 [[4 (1 METHYL 1,2,5,6 TETRAHYDROPYRIDIN 3 YL) 1,2,5 THIADIAZOL 3 YL]OXY]NONYL]PIPERIDIN 1 YL] 1,2,3,4 TETRAHYDROQUINOLIN 2 ONE; ALCOHOL DERIVATIVE; BETA ARRESTIN 2; GUANINE NUCLEOTIDE BINDING PROTEIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M4 RECEPTOR; PIRENZEPINE; RADIOLIGAND; UNCLASSIFIED DRUG; XANOMELINE; 1-(3-(4-BUTYL-1-PIPERIDINYL)PROPYL)-3,4-DIHYDRO-2(1H)-QUINOLINONE; MUSCARINIC AGENT; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; THIADIAZOLE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CHEMICAL STRUCTURE; CHO CELL LINE; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; LIGAND BINDING; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; CRICETULUS; DRUG EFFECTS; MOLECULAR DOCKING; SYNTHESIS;

ANIMALS; CHO CELLS; CRICETULUS; MOLECULAR DOCKING SIMULATION; MUSCARINIC AGONISTS; PIPERIDINES; PYRIDINES; QUINOLONES; RECEPTOR, MUSCARINIC M1; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 84923829087     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501173q     Document Type: Article

References (39)

1. Abrams, P.; Andersson, K. E.; Buccafusco, J. J.; Chapple, C.; Chet de Groat, W.; Fryer, A. D.; Kay, G.; Laties, A.; Nathanson, N. M.; Pasricha, P. J.; Wein, A. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder Br. J. Pharmacol. 2006, 148, 565-578
2. Volpicelli, L. A.; Levey, A. I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus Prog. Brain Res. 2004, 145, 59-66
3. Caccamo, A.; Oddo, S.; Billings, L. M.; Green, K. N.; Martinez-Coria, H.; Fisher, A.; LaFerla, F. M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice Neuron 2006, 49, 671-682
4. Davis, A. A.; Fritz, J. J.; Wess, J.; Lah, J. J.; Levey, A. I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo J. Neurosci. 2010, 30, 4190-4196
5. Dean, D. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia Neuropsychopharmacology 2004, 29, 1583-1584
6. Watson, J.; Brough, S.; Coldwell, M. C.; Gager, T.; Ho, M.; Hunter, A. J.; Jerman, J.; Middlemiss, D. N.; Riley, G. J.; Brown, A. M. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors Br. J. Pharmacol. 1998, 125, 1413-1420
7. Bodick, N. C.; Offen, W. W.; Levey, A. I.; Cutler, N. R.; Gauthier, S. G.; Satlin, A.; Shannon, H. E.; Tollefson, G. D.; Rasmussen, K.; Bymaster, F. P.; Hurley, D. J.; Potter, W. Z.; Paul, S. M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease Arch. Neurol. 1997, 54, 465-473
8. Bodick, N. C.; Offen, W. W.; Shannon, H. E.; Satterwhite, J.; Lucas, R.; Van Lier, R.; Paul, S. M. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease Alzheimer Dis. Assoc. Disord. 1997, 11, S16-S22
9. Shekhar, A.; Potter, W. Z.; Lightfoot, J.; Lienemann, J.; Dube, S.; Mallinckrodt, C.; Bymaster, F. P.; McKinzie, D. L.; Felder, C. C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia Am. J. Psychiatry 2008, 165, 1033-1039
10. Spalding, T. A.; Trotter, C.; Skjaerbaek, N.; Messier, T. L.; Currier, E. A.; Burstein, E. S.; Li, D.; Hacksell, U.; Brann, M. R. Discovery of an ectopic activation site on the M1 muscarinic receptor Mol. Pharmacol. 2002, 61, 1297-1302
11. Langmead, C. J.; Austin, N. E.; Branch, C. L.; Brown, J. T.; Buchanan, K. A.; Davies, C. H.; Forbes, I. T.; Fry, V. A.; Hagan, J. J.; Herdon, H. J.; Jones, G. A.; Jeggo, R.; Kew, J. N.; Mazzali, A.; Melarange, R.; Patel, N.; Pardoe, J.; Randall, A. D.; Roberts, C.; Roopun, A.; Starr, K. R.; Teriakidis, A.; Wood, M. D.; Whittington, M.; Wu, Z.; Watson, J. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 Br. J. Pharmacol. 2008, 154, 1104-1115
12. Kruse, A. C.; Kobilka, B. K.; Gautam, D.; Sexton, P. M.; Christopoulos, A.; Wess, J. Muscarinic acetylcholine receptors: novel opportunities for drug development Nature Rev. Drug Discovery 2014, 13, 549-560
13. Valant, C.; Lane, J. R.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 153-178
14. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands targeting GPCRs ChemMedChem 2011, 6, 963-974
15. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66
16. Moser, U.; Gubitz, C.; Galvan, M.; Immel-Sehr, A.; Lambrecht, G.; Mutshcler, E. Aliphatic and heterocyclic analogues of arecaidine propargyl ester. Structure-activity relationships of mono- and bivalent ligands at muscarinic M1, M4, M2, and M3 receptor subtypes Arzneim. Forsch. 1995, 45, 449-455
17. Christopoulos, A.; Grant, M. K.; Ayoubzadeh, N.; Kim, O. N.; Sauerberg, P.; Jeppesen, L.; El-Fakahany, E. E. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists J. Pharmacol. Exp. Ther. 2001, 298, 1260-1268
18. Rajeswaran, W. G.; Cao, Y.; Huang, X. P.; Wroblewski, M. E.; Colclough, T.; Lee, S.; Liu, F.; Nagy, P. I.; Ellis, J.; Levine, B. A.; Nocka, K. H.; Messer, W. S., Jr. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists J. Med. Chem. 2001, 44, 4563-4576
19. Disingrini, T.; Muth, M.; Dallanoce, C.; Barocelli, E.; Bertoni, S.; Kellershohn, K.; Mohr, K.; De Amici, M.; Holzgrabe, U. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors J. Med. Chem. 2006, 49, 366-372
20. Fang, L.; Jumpertz, S.; Zhang, Y.; Appenroth, D.; Fleck, C.; Mohr, K.; Tränkle, C.; Decker, M. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors J. Med. Chem. 2010, 53, 2094-2103
21. May, L. T.; Avlani, V. A.; Langmead, C. J.; Herdon, H. J.; Wood, M. D.; Sexton, P. M.; Christopoulos, A. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors Mol. Pharmacol. 2007, 72, 463-476
22. Piergentili, A.; Quaglia, W.; Del Bello, F.; Giannella, M.; Pigini, M.; Barocelli, E.; Bertoni, S.; Matucci, R.; Nesi, M.; Bruni, B.; Di Vaira, M. Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation Bioorg. Med. Chem. 2009, 17, 8174-8185
23. Lohse, M. J.; Nuber, S.; Hoffmann, C. Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling Pharmacol. Rev. 2012, 64, 299-336
24. Galés, C.; Rebois, R. V.; Hogue, M.; Trieu, P.; Breit, A.; Hébert, T. E.; Bouvier, M. Real-time monitoring of receptor and G-protein interactions in living cells Nature Methods 2005, 2, 177-184
25. Luo, J.; Busillo, J. M.; Benovic, J. L. M3 muscarinic acetylcholine receptor-mediated signaling is regulated by distinct mechanisms Mol. Pharmacol. 2008, 74, 338-347
26. Ulysse, L. G.; Chmielewski, J. Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease Bioorg. Med. Chem. Lett. 1998, 8, 3281-3286
27. Sams, A. G.; Hentzer, M.; Mikkelsen, G. K.; Larsen, K.; Bundgaard, C.; Plath, N.; Christoffersen, C. T.; Bang-Andersen, B. Discovery of N -{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential J. Med. Chem. 2010, 53, 6386-6397
28. Kane, B. E.; Grant, M. K.; El-Fakahany, E. E.; Ferguson, D. M. Synthesis and evaluation of xanomeline analogs-probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor Bioorg. Med. Chem. 2008, 16, 1376-1392
29. Avlani, V. A.; Langmead, C. J.; Guida, E.; Wood, M. D.; Tehan, B. G.; Herdon, H. J.; Watson, J. M.; Sexton, P. M.; Christopoulos, A. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor Mol. Pharmacol. 2010, 78, 94-104
30. Shenoy, S. K.; Lefkowitz, R. J. β-Arrestin-mediated receptor trafficking and signal transduction Trends Pharmacol. Sci. 2011, 32, 521-533
31. Kenakin, T. Functional selectivity and biased receptor signaling J. Pharmacol. Exp. Ther. 2011, 336, 296-302
32. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hübner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013, 504, 101-106
33. Dörje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes J. Pharmacol. Exp. Ther. 1991, 256, 727-733
34. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 1976, 72, 248-254
35. Munson, P. J.; Rodbard, D. LIGAND: A versatile computerized approach for characterization of ligand-binding systems Anal. Biochem. 1980, 107, 220-239
36. Namkung, Y.; Dipace, C.; Javitch, J. A.; Sibley, D. R. G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor J. Biol. Chem. 2009, 284, 15038-15051
37. Galés, C.; Van Durm, J. J.; Schaak, S.; Pontier, S.; Percherancier, Y.; Audet, M.; Paris, H.; Bouvier, M. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes Nature Struct. Mol. Biol. 2006, 13, 778-786
38. Chan, P.; Thomas, C. J.; Sprang, S. R.; Tall, G. G. Molecular chaperoning function of Ric-8 is to fold nascent heterotrimeric G protein α subunits Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 3794-3799
39. Guan, X. M.; Tong Sun, K.; Kobilka, B. K. Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide J. Biol. Chem. 1992, 267, 21995-21998